EcoDrugPlus

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSACLG00000022691
Gene Symbol: P2RY6
2 Cross references
183 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSACLG00000009561
Gene Symbol: RAMP1
1 Cross references
183 Possible Orthologues:

Receptor Activity-Modifying Protein 1-Like

Ensembl ID : ENSACLG00000007147
Gene Symbol: LOC113007272
3 Cross references
190 Possible Orthologues:

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSACLG00000020558
Gene Symbol: RIPK1
3 Cross references
198 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-3-Like

Ensembl ID : ENSACLG00000006083
Gene Symbol: LOC113013517
3 Cross references
207 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSACLG00000010253
Gene Symbol: RPTOR
3 Cross references
214 Possible Orthologues:

Renin-Like

Ensembl ID : ENSACLG00000024519
Gene Symbol: LOC113013404
3 Cross references
220 Possible Orthologues:

Ret Proto-Oncogene

Ensembl ID : ENSACLG00000020251
Gene Symbol: RET
3 Cross references
204 Possible Orthologues:

Retinoic Acid Receptor Rxr-Beta-A-Like

Ensembl ID : ENSACLG00000002108
Gene Symbol: LOC113032455
3 Cross references
211 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSACLG00000017588
Gene Symbol: RARB
4 Cross references
393 Possible Orthologues:

Retinoic Acid Receptor Beta-Like

Ensembl ID : ENSACLG00000007410
Gene Symbol: LOC113032484
2 Cross references
380 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSACLG00000006785
Gene Symbol: RARG
4 Cross references
383 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).